| Title |
Belantamab Mafodotin (GSK2857916) Drives Immunogenic Cell Death and Immune-mediated Antitumor Responses In VivoGSK2857916 Drives ICD and Adaptive Antitumor Responses
|
|---|---|
| Published in |
Molecular Cancer Therapeutics, July 2021
|
| DOI | 10.1158/1535-7163.mct-21-0035 |
| Pubmed ID | |
| Authors |
Rocio Montes de Oca, Alireza S. Alavi, Nick Vitali, Sabyasachi Bhattacharya, Christina Blackwell, Krupa Patel, Laura Seestaller-Wehr, Heather Kaczynski, Hong Shi, Eric Dobrzynski, Leslie Obert, Lyuben Tsvetkov, David C. Cooper, Heather Jackson, Paul Bojczuk, Sabrina Forveille, Oliver Kepp, Allan Sauvat, Guido Kroemer, Mark Creighton-Gutteridge, Jingsong Yang, Chris Hopson, Niranjan Yanamandra, Christopher Shelton, Patrick Mayes, Joanna Opalinska, Mary Barnette, Roopa Srinivasan, James Smothers, Axel Hoos |
X Demographics
The data shown below were collected from the profiles of 9 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 2 | 22% |
| Mexico | 1 | 11% |
| Unknown | 6 | 67% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 6 | 67% |
| Scientists | 2 | 22% |
| Science communicators (journalists, bloggers, editors) | 1 | 11% |
Mendeley readers
The data shown below were compiled from readership statistics for 36 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 36 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 8 | 22% |
| Researcher | 5 | 14% |
| Other | 3 | 8% |
| Student > Postgraduate | 2 | 6% |
| Student > Bachelor | 2 | 6% |
| Other | 3 | 8% |
| Unknown | 13 | 36% |
| Readers by discipline | Count | As % |
|---|---|---|
| Immunology and Microbiology | 6 | 17% |
| Biochemistry, Genetics and Molecular Biology | 5 | 14% |
| Medicine and Dentistry | 4 | 11% |
| Pharmacology, Toxicology and Pharmaceutical Science | 2 | 6% |
| Chemistry | 2 | 6% |
| Other | 5 | 14% |
| Unknown | 12 | 33% |
Attention Score in Context
This research output has an Altmetric Attention Score of 9. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 15 June 2023.
All research outputs
#3,925,655
of 24,293,076 outputs
Outputs from Molecular Cancer Therapeutics
#740
of 3,963 outputs
Outputs of similar age
#85,369
of 426,744 outputs
Outputs of similar age from Molecular Cancer Therapeutics
#10
of 60 outputs
Altmetric has tracked 24,293,076 research outputs across all sources so far. Compared to these this one has done well and is in the 83rd percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,963 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.6. This one has done well, scoring higher than 81% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 426,744 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 79% of its contemporaries.
We're also able to compare this research output to 60 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 85% of its contemporaries.